{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:03:03Z","timestamp":1781330583729,"version":"3.54.1"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,3,8]],"date-time":"2004-03-08T00:00:00Z","timestamp":1078704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold><jats:bold> Background:\u2002<\/jats:bold> Histological recurrence of the hepatitis C virus (HCV) occurs in the majority of persons transplanted for cirrhosis as a result of HCV. Herein we analyze our experience with the use of both conventional and pegylated (PEG) interferon (IFN) in combination with ribavirin (RBV) in liver transplant recipients with recurrent HCV.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Patients transplanted between 1992 and 2001 with post\u2010orthotopic liver transplantation (OLT) histological recurrence of HCV, and who were treated with at least 6\u2003months of IFN or PEG\u2010IFN in combination with RBV were included in this analysis. A retrospective chart review was performed.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> A total of 31 patients were included. Fifteen were treated with IFN\/RBV and 16 with PEG\u2010IFN\/RBV. Of these 16, 11 had been begun on IFN\/RBV and were changed to PEG\u2010IFN\/RBV because of persistent viremia. Three patients (20%) in the IFN\/RBV group and six patients (37.5%) in the PEG\u2010IFN\/RBV group experienced a virologic response (VR) on therapy. Of the six patients experiencing VR in the PEG\u2010IFN\/RBV group, three (50%) were IFN\/RBV non\u2010responders. There were two sustained VRs (SVR). The 65.6% of all patients experienced a biochemical response (BR) on therapy. Seven deaths were observed. Dose modifications of IFN or PEG\u2010IFN (87.1%) and RBV (80.6%) and the requirement for hematopoietic growth factors were frequent.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Treatment of recurrent HCV infection with combination of IFN or PEG\u2010IFN and RBV produced an on\u2010therapy VR in 29% and BR in 65% of patients. Hematologic toxicity and dose modifications were frequent. Our experience with antiviral therapy for HCV post\u2010OLT remains disappointing but PEG\u2010IFN\u2003+\u2003RBV appears to produce VR in a sizable portion of IFN\u2003+\u2003RBV non\u2010responders.<\/jats:p>","DOI":"10.1046\/j.1399-0012.2003.00145.x","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T07:37:28Z","timestamp":1103701048000},"page":"166-173","source":"Crossref","is-referenced-by-count":85,"title":["Pegylated interferon \u03b1\u20102b plus ribavirin in the treatment of post\u2010liver transplant recurrent hepatitis C"],"prefix":"10.1111","volume":"18","author":[{"given":"Andrew S","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul K","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thiim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Benedict Cosimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,3,8]]},"reference":[{"key":"e_1_2_18_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2001.001003197.x"},{"key":"e_1_2_18_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.22447"},{"key":"e_1_2_18_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9942"},{"key":"e_1_2_18_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200402"},{"key":"e_1_2_18_6_2","first-page":"1222","article-title":"Alpha\u2010interferon for acute hepatitis C in liver patients","volume":"27","author":"Vargas V","year":"1995","journal-title":"Transplant Proc"},{"key":"e_1_2_18_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.33968"},{"key":"e_1_2_18_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260236"},{"key":"e_1_2_18_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200103150-00019"},{"key":"e_1_2_18_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(96)00248-5"},{"key":"e_1_2_18_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00554-5"},{"key":"e_1_2_18_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36162"},{"key":"e_1_2_18_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.34968"},{"key":"e_1_2_18_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_18_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_18_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80226-6"},{"key":"e_1_2_18_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109270-00015"},{"key":"e_1_2_18_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50095"},{"key":"e_1_2_18_19_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hep.1840210107","article-title":"Severe or multiple rejection episodes lead to increased early recurrence of hepatitis C following liver transplantation","volume":"21","author":"Sheiner PA","year":"1995","journal-title":"Hepatology"},{"key":"e_1_2_18_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904010-00002"},{"key":"e_1_2_18_21_2","unstructured":"ChungR AndersenJ AlstonMet al.A randomized controlled trial of pegylated interferon\u20132a with ribavirin vs interferon\u2010\u03b1\u20102a with ribavirin for the treatment of chronic HCV in HIV con\u2010infection: ACTG A5071. Seattle WA: 9th Conference on Retroviruses and Opportunistic Infections 2002(Abstract LB\u201015)."},{"key":"e_1_2_18_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33993"},{"key":"e_1_2_18_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280334"},{"key":"e_1_2_18_24_2","first-page":"A632","article-title":"Interferon alfa\u20102b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C end\u2010stage liver disease results of a multicenter, randomized trial","volume":"122","author":"Reddy R","year":"2002","journal-title":"Gastroenterology"},{"key":"e_1_2_18_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(00)02508-2"},{"key":"e_1_2_18_26_2","first-page":"297A","article-title":"Long\u2010term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low\u2010accelerating\u2010dose regimen)","volume":"36","author":"Everson GT","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_18_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200102270-00005"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1399-0012.2003.00145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1399-0012.2003.00145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:57:18Z","timestamp":1697453838000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1399-0012.2003.00145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1046\/j.1399-0012.2003.00145.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1399-0012.2003.00145.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,8]]}}}